Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.55 |
| ▸ | BCHE | P06276 | 1/20 | 0.55 |
| ▸ | ACHE | P22303 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | GLS | O94925 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30797187 | 1.00 | MAOB (0.55) | MAOBBCHEACHETDP1L3MBTL1 | |
| SCHEMBL504643 | 0.95 | MAOB (0.56) | MAOBBCHEACHETDP1L3MBTL1 | |
| SCHEMBL22777375 | 0.93 | TDP1 (0.58) | MAOBBCHEACHETDP1L3MBTL1 | |
| SCHEMBL29798960 | 0.93 | TDP1 (0.58) | MAOBBCHEACHETDP1L3MBTL1 | |
| SCHEMBL30601913 | 0.93 | TDP1 (0.58) | MAOBBCHEACHETDP1L3MBTL1 | |
| SCHEMBL28696286 | 0.93 | TDP1 (0.58) | MAOBBCHEACHETDP1L3MBTL1 | |
| SCHEMBL103036 | 0.89 | GLS (0.55) | MAOBBCHEACHETDP1L3MBTL1 | |
| SCHEMBL19429938 | 0.84 | MAOB (0.50) | MAOBBCHEACHETDP1L3MBTL1 | |
| SCHEMBL7347496 | 0.83 | TDP1 (0.54) | TDP1L3MBTL1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL21069507 | 0.82 | MAPT (0.51) | MAOBBCHEACHETDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 168 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025133660-A1 | NOVEL COMPOUNDS FOR HOST DIRECTED ANTIVIRAL STRATEGY | SORBONNE UNIVERSITE (FR) | 2025-06-26 | — | — | WO | disclosed |
| WO-2025132449-A1 | NOVEL COMPOUNDS FOR HOST DIRECTED ANTIVIRAL STRATEGY | SORBONNE UNIVERSITE (FR) | 2025-06-26 | — | — | WO | disclosed |
| US-20240246913-A1 | 2-CARBOXYL-INDOLE INHIBITORS OF METALLO-BETA-LACTAMASES | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2024-07-25 | — | — | US | disclosed |
| EP-4347563-A1 | 2-CARBOXYL-INDOLE INHIBITORS OF METALLO-BETA-LACTAMASES | Oxford University Innovation Limited (GB) | 2024-04-10 | — | — | EP | disclosed |
| CN-117677606-A | 2-carboxy-indole inhibitors of metallo-beta-lactamase | 牛津大学创新有限公司 | 2024-03-08 | — | — | CN | disclosed |
| US-11833208-B2 | PLK1 selective degradation inducing compound | UPPTHERA, INC. (KR) | 2023-12-05 | — | — | US | disclosed |
| US-11833208-B2 | PLK1 selective degradation inducing compound | UPPTHERA, INC. (KR) | 2023-12-05 | — | — | US | disclosed |
| US-20230372498-A1 | PLK1 SELECTIVE DEGRADATION INDUCING COMPOUND | UPPTHERA (KR) | 2023-11-23 | — | — | US | disclosed |
| US-20230372498-A1 | PLK1 SELECTIVE DEGRADATION INDUCING COMPOUND | UPPTHERA (KR) | 2023-11-23 | — | — | US | disclosed |
| US-20230331720-A1 | MEDIUM- OR MACRO-CYCLIC BENZYL-SUBSTITUTED HETEROCYCLE DERIVATIVES AND THEIR USES AS OREXIN-2 RECEPTOR AGONISTS | OXFORD FINANCE LLC | 2023-10-19 | — | — | US | disclosed |
| CN-1206395-A | Pesticide compounds, compositions and process for preparation thereof | CHINOIN GYOGYSZER ES VEGYESZET (HU) | 1999-01-27 | — | — | CN | disclosed |
| EP-0827495-A4 | SUBSTITUTED-PENT-4-YNOIC ACIDS | SMITHKLINE BEECHAM CORP (US) | 1998-11-04 | — | — | EP | disclosed |
| EP-0862545-A2 | PESTICIDE COMPOUNDS, COMPOSITIONS AND PROCESS FOR THE PREPARATION THEREOF | CHINOIN Gyògyszer és Vegyészeti Termékek Gyára RT. (HU) | 1998-09-09 | — | — | EP | disclosed |
| EP-0827495-A1 | SUBSTITUTED-PENT-4-YNOIC ACIDS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-03-11 | — | — | EP | disclosed |
| WO-1997019040-A2 | PESTICIDE COMPOUNDS, COMPOSITIONS AND PROCESS FOR THE PREPARATION THEREOF | Chinoin Gyógyszer és Vegyészeti Termékek Gyára Rt. (HU) | 1997-05-29 | — | — | WO | disclosed |
| WO-1997003945-A1 | SUBSTITUTED-PENT-4-YNOIC ACIDS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-02-06 | — | — | WO | disclosed |
| EP-0189307-B1 | ANTIHISTAMINE-H2 ALKYNE THIADIAZOLE DERIVATIVES | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1990-08-29 | — | — | EP | disclosed |
| US-4732980-A | HISTAMINE H-2 ANTAGONISTS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1988-03-22 | — | — | US | disclosed |
| US-4663331-A | HISTAMINE H2-ANTAGONIST | SMITHKLINE & FRENCH LABORATORIES LIMITED (GB) | 1987-05-05 | — | — | US | disclosed |
| EP-0189307-A2 | Antihistamine-H2 alkyne thiadiazole derivatives | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1986-07-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230372498-A1 | PLK1 SELECTIVE DEGRADATION INDUCING COMPOUND | PLK1, BUB1B, BUB1 | MAOB 3258/4885BCHE 2855/4885ACHE 3353/4885 |
| US-20240246913-A1 | 2-CARBOXYL-INDOLE INHIBITORS OF METALLO-BETA-LACTAMASES | IDO2, IDO1, COMT | MAOB 13/4885BCHE 51/4885ACHE 46/4885 |
| US-20230331720-A1 | MEDIUM- OR MACRO-CYCLIC BENZYL-SUBSTITUTED HETEROCYCLE DERIVATIVES AND THEIR USES AS OREXIN-2 RECEPTOR AGONISTS | HCRTR2, HCRTR1, CRHR2 | MAOB 348/4885BCHE 690/4885ACHE 2863/4885 |
| US-11833208-B2 | PLK1 selective degradation inducing compound | PLK1, BUB1B, BUB1 | MAOB 3258/4885BCHE 2855/4885ACHE 3353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.